Document is current
Any future updates will be listed below
-
Authors
Riskedal, Espen
Jugessur, Astanand
Syversen, Silje Watterdal
Hadley, Cathrine Lund
Harris, Jennifer R.
Mjaavatten, Maria Dahl
Sexton, Joe
Neumann, Janis
Brinkmann, Gina Hetland
Goll, Guro Løvik
Stenvik, Grethe-Elisabeth
Bøås, Håkon
Søraas, Arne
Kalleberg, Karl Trygve
Lillegraven, Siri
Haavardsholm, Espen A.
-
Funding
Funding for this research was provided by:
Norges Forskningsråd (296199, 262700, 328657, 296199, 262700, 328657, 328657, 296199, 328657, 328657, 296199, 296199, 328657, 328657)
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 10 September 2025
First Online: 17 October 2025
Declarations
:
: The study protocol for the current analysis was approved by an independent ethics committee, the Regional Committee for Medical and Health Research Ethics South-East; reference number 26325. Additionally, all individual cohorts had ethical approvals according to national ethical guidelines as described previously [–].
: Not applicable.
: Disclosures: ER, AS and KTK are founders, shareholders and employees of Age Labs AS; CLH and JS are employees of Age Labs AS; GLG, Galapagos, Abbvie, UCB, Pfizer; EAH, Pfizer, AbbVie, Eli Lilly, UCB, Roche (research grants paid to Diakonhjemmet Hospital in relation to the ARCTIC trial); All others, None.
